MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer), who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested a total of €8 million in MedDay.

MedDay addresses areas of unmet need in neurological and psychiatric diseases through the brain metabolism. This approach relies on unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism.

Our vision is to:
  • Treat neurological diseases and manifestations by treating metabolic pathway modifications.
  • Develop compounds that have a known activity in neurological metabolic pathways.
  • Focus on fast and meaningful clinical proof of concept in a small number of patients. We believe that, if a drug has an effect on a neurodegenerative disease, we should be able to demonstrate the effect a small group of patients. Once the proof of concept is established, the results have to be confirmed in properly designed phase 2/3 placebo-controlled studies involving a larger number of patients.
  • Build Intellectual Property based on formulation/use patents.
  • Develop strong academic collaborations to decipher the mechanism of action of the selected drugs in adequate models.
Our ethics
  • MedDay prioritizes diseases of the central nervous system with high unmet medical need.
  • We place patients and their families at the heart of our mission: our approach is designed to bring safe and efficacious drugs to patients in a short period of time.
  • To achieve this goal, MedDay mitigates the risks of early development by:
    1. Investigating diseases directly in patients’ cerebrospinal fluid (through the SPECMET platform);
    2. Using molecules of the pharmacopeia with an acceptable safety profile;
    3. Focusing on the clinical proof of efficacy in a small number of patients before moving to full pharmaceutical development.

Leave a Reply

Your email address will not be published. Required fields are marked *